Posts

As the economy ebbs and flows, pharma and biotech companies alike are feeling the pressure to cut costs. From rapid inflation to the ever-changing regulatory landscape, many are looking for ways to reduce their burn rate.

Six months after its official launch by Flagship Ventures, Massachusetts-based Vesalius Therapeutics is laying off 43% of its staff. With a current headcount of 67, the company is slashing 29 jobs.